Vitality Watch

Dossier pubmed review 31-jul-2026
Narrative review or expert overview without new data

Senescence of the immune system in SLE: Pathogenic mechanisms and therapeutic implications.

Key claim: Immunosenescence drives SLE pathogenesis via senescent CD28−CD57+KLRG1+ T cells, age-associated B cells producing autoantibodies, and pro-inflammatory myeloid skewing with SASP-like mediators, motivating therapies that mitigate immune aging.

Abstract

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by loss of immune tolerance and multi-organ inflammation. Although its pathogenesis involves multiple factors, the peak incidence of SLE in individuals over 48 years of age points to immunosenescence as a key driver of the disease.Even in younger patients, SLE frequently often presents as premature aging of the immune system. This review synthesizes recent advances in understanding how immunosenescence drives pathogenesis through immune dysregulation across major lymphocyte and myeloid subsets. Within the chronic inflammatory microenvironment, replicative exhaustion of T cells leads to accelerated telomere attrition, persistent activation of the DNA damage response, and telomerase dysfunction. This cascade culminates in the accumulation of senescent T cells displaying a characteristic CD28CD57KLRG1phenotype, accompanied by a pro-inflammatory state defined by enhanced cytotoxicity and impaired regulatory function. These characteristics correlated directly with disease activity and cumulative organ damage. The process arises from the interplay of metabolic reprogramming and epigenetic remodeling. In parallel, age-associated B cells (ABCs) accumulate, producing high-affinity anti-dsDNA and other autoantibodies, and potentiating inflammation via enhanced antigen presentation. Meanwhile, an aged bone-marrow microenvironment together with clonal hematopoiesis skews monocyte and macrophage polarization toward a pro-inflammatory (M1) profile. These cells show reduced phagocytic capacity and heightened secretion of senescence-associated secretory phenotype (SASP)-like mediators, further driving inflammaging. This review synthesizes current insights into the relationship between SLE risk and immunosenescence. We discuss the mechanisms through which immune aging instigates autoimmunity and explore emerging therapeutic strategies aimed at mitigating immunosenescence.

Why this matters

Immunosenescence drives SLE pathogenesis via senescent CD28−CD57+KLRG1+ T cells, age-associated B cells producing autoantibodies, and pro-inflammatory myeloid skewing with SASP-like mediators, motivating therapies that mitigate immune aging.

Source

Link

Briefing card

Senescence of the immune system in SLE: Pathogenic mechanisms and therapeutic implications.
Stage: review · pubmed · 31-jul-2026

Immunosenescence drives SLE pathogenesis via senescent CD28−CD57+KLRG1+ T cells, age-associated B cells producing autoantibodies, and pro-inflammatory myeloid skewing with SASP-like mediators, motivating therapies that mitigate immune aging.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.autrev.2026.104152

build build 880 · 2bcef25 · 2026-11-18